Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma.
about
Imaging of HCC-Current State of the ArtPrognostication and response assessment in liver and pancreatic tumors: The new imagingImplementation of dual-source RF excitation in 3 T MR-scanners allows for nearly identical ADC values compared to 1.5 T MR scanners in the abdomenImaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoringRecent Advances in CT and MR Imaging for Evaluation of Hepatocellular CarcinomaDiffusion-weighted imaging of the liver: techniques and applications.Diffusion MRI in early cancer therapeutic response assessment.Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survivalQuantitative multiparametric PROPELLER MRI of diethylnitrosamine-induced hepatocarcinogenesis in wister rat modelDiffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy.Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlationApplications of molecular imaging.Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma.Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical reviewEvidence-based diagnosis and locoregional therapy for hepatocellular carcinoma.Diffusion-weighted and Gd-EOB-DTPA-contrast-enhanced magnetic resonance imaging for characterization of tumor necrosis in an animal model.Diffusion-weighted MRI in abdominal oncology: clinical applications.Radioembolization for hepatocellular carcinoma using TheraSphere®.Advanced renal mass imaging: diffusion and perfusion MRI.Oncologic applications of diffusion-weighted MRI in the body.Diffusion-weighted imaging of the liver: an update.Imaging tumor response following liver-directed intra-arterial therapy.Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma.Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.Functional magnetic resonance imaging in an animal model of pancreatic cancer.Quantitative Aspects of Diffusion-weighted Magnetic Resonance Imaging in Rectal Cancer Response to Neoadjuvant Therapy.Predictive value of apparent diffusion coefficient in evaluation of colorectal carcinoma hepatic metastases' response to radiofrequency ablation.Intravoxel incoherent motion diffusion-weighted MR imaging of the liver using respiratory-cardiac double triggering.Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.Evaluation of therapeutic response to concurrent chemoradiotherapy in patients with cervical cancer using diffusion-weighted MR imaging.Does diffusion-weighted imaging improve therapy response evaluation in patients with hepatocellular carcinoma after radioembolization? comparison of MRI using Gd-EOB-DTPA with and without DWI.Diffusion-weighted MRI of the liver for early tumor response assessment: Promising technique but evidence is still lacking.Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma.
P2860
Q26768463-30F35CB7-FDDF-4BFF-95F0-43971925BE9DQ27021568-3439FB29-C061-42C8-91B5-507F1793A063Q28731628-E0C2AFDC-F294-4FE8-A16B-39CA934E4ADDQ30436747-A0A2B621-B736-4F16-8151-0A6082137019Q30448049-418B6640-C604-4D36-BFD4-801F02C67A7BQ30840354-871DE458-F694-4372-A1FE-DAC66E044DBDQ31037179-F27D3CFB-2DA3-47BF-8A99-9F0DA1941C50Q33925521-F97564B3-1DA7-4530-B35C-5C356BCFEF3BQ34001900-D7EAD11C-77FB-4F0D-8C13-8CEF2F7D80B5Q34256394-CDF03FAF-4619-4111-AF11-D9CD510F9989Q34681148-4695B7B5-0A15-4171-9698-BBCE0E6023B0Q34982068-A41F7855-C59B-421F-B6E0-E00430601E46Q35082412-78E1C0C1-B3B4-45AE-BC2B-BA372B2752BEQ35163735-78892D99-15F0-4FBC-99F9-F2FDD49F698AQ36352452-DB2F52E7-5352-4B83-8FE0-2F3AABD453BAQ36423114-769F6AAF-DDF9-49F9-9D08-F1F2581F5D35Q37073257-C1014534-EBD6-4659-8253-511ACA15A1B8Q37113543-D4176670-799C-4594-A736-3ACE3ADD5FC7Q37353089-05EA9634-D983-43FD-B5A7-813E3D97EBBCQ37407639-9A39ED3C-7A0E-4230-8CF5-EB01D0690357Q37689666-3018029E-A9BB-4367-BB2B-2F7DD8E7F17AQ37872543-51577AF9-3B62-49D0-AD7B-4E95E3AC66B6Q37955823-8DC66E2A-3AB4-4074-976A-A6198004B14AQ37978220-08EEC9CF-478C-4744-A6FB-08E61C86FA3CQ38100027-CB185D12-8188-4D51-B22A-398432A33015Q38117579-FE6127E1-C699-481D-A039-0813DF333BC7Q38155510-32D73988-74C6-499D-A65E-F3D1266A7004Q38269850-92F0809C-3226-4F84-B9CA-E1EB1A88945EQ39940937-F0FB06D7-C9D5-4644-B134-D425D9FE7E93Q41678135-D36ACA9E-F7EA-4C44-AB8F-77C927C6F98FQ44195395-CCC68E57-357B-4E6A-8620-257525E34F12Q47107800-9E40DAE3-A138-451D-AB31-2DFC8C1CE4BCQ48156557-DF4DFDB8-546F-4844-A5DF-1681E706073DQ53359183-6C804806-D8EE-446C-B542-AC864E0BCFBBQ53666805-622B0200-7901-4ED9-AAC8-4E55D71AB68BQ53793211-E0D5FA28-B8E0-428E-B49D-98007A44CBC2Q55227929-53856F65-20F0-4B18-B98E-60B5E7D9A384
P2860
Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Functional MR imaging assessme ...... able hepatocellular carcinoma.
@en
Functional MR imaging assessme ...... able hepatocellular carcinoma.
@nl
type
label
Functional MR imaging assessme ...... able hepatocellular carcinoma.
@en
Functional MR imaging assessme ...... able hepatocellular carcinoma.
@nl
prefLabel
Functional MR imaging assessme ...... able hepatocellular carcinoma.
@en
Functional MR imaging assessme ...... able hepatocellular carcinoma.
@nl
P2093
P1476
Functional MR imaging assessme ...... able hepatocellular carcinoma.
@en
P2093
Diane K Reyes
Ihab R Kamel
Jean-Francois H Geschwind
P356
10.1016/J.JVIR.2006.10.005
P433
P577
2007-01-01T00:00:00Z